Study details real-world data on Leqembi treatment persistence over time.
- Study highlights real-world effectiveness of Leqembi
- Focus on treatment persistence over time
- Relevance to Alzheimer's disease management
New research presented at the ADPD 2026 conference highlights the long-term treatment persistence of Leqembi (lecanemab-irmb) in patients with Alzheimer's disease. This study provides real-world data addressing how consistently patients receive this treatment over extended periods. Understanding Leqembi treatment persistence is crucial for evaluating its effectiveness in patient care.
The findings reveal that patients treated with Leqembi maintained their treatment regimen over time, contributing to sustained engagement in therapy. This aspect of long-term treatment is significant as it may affect clinical outcomes and overall quality of life for individuals living with Alzheimer's disease. The real-world data also underscore the importance of ongoing support for patients on this therapy.
As Alzheimer’s disease continues to affect millions, insights from this research play a vital role in informing clinicians about patient adherence and treatment options. By focusing on real-world scenarios, healthcare professionals can better understand how to optimize the use of Leqembi in their patient populations.
